Adding transcatheter mitral-valve repair to the treatment plan of patients who have heart failure (HF) with moderate to severe functional mitral regurgitation (FMR), in addition to guideline-recommended medical therapy, leads to lower rates of first or recurrent HF hospitalization or cardiovascular death, according to results from the RESHAPE-HF2 clinical trial.